Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01935232 · ClinicalTrials.gov registry record

Bindex Ultrasonometer for Osteoporosis Diagnostics

A clinical trial, sponsored by Bone Index Finland.

Terminated
Registry status
135
Enrollment target

NCT01935232: Clinical Trial study, sponsored by Bone Index Finland.

NCT01935232 is a clinical trial that was terminated before completion, run by Bone Index Finland. The registered enrollment target is 135 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01935232 was terminated before completion, sponsored by Bone Index Finland.

TERMINATED
Registry status
135 participants
Enrollment target

Study Summary

Osteoporosis is a disease that leads to impaired skeletal strength and increased fracture risk. Among 200 million osteoporotic patients (Tarantino, Cannata et al. 2007) most are diagnosed only after a fracture. We expect with our aging population to see a significant increase in the prevalence of osteoporosis. It is estimated that over 75% of osteoporotic patients are not diagnosed and do not receive treatment for their condition. This research plan describes a study for clinical validation of the novel ultrasound device (Bindex®, Bone Index Finland Ltd.). In a preliminary study, the technique has been validated in a Finnish postmenopausal woman population of 285 healthy and 56 osteoporotic subjects (n = 341 in total). Significant and good correlation was observed between Density Index (DI) determined with Bindex and femoral neck bone mineral density determined with DXA (r = 0.65 - 0.70). In addition, with determination of 90% sensitivity and specificity thresholds, significant number (65-75%) of patients could be diagnosed without additional verification with DXA. For validation of the technique in US population, our study plan is presented for determination of diagnostic thresholds for osteoporosis. Taken together, DI with Bindex, lumbar spine and femoral bone BMD with DXA are obtained from 500 postmenopausal women and 140 men. The study will be carried out at the HealthEast Osteoporosis Care service in Woodbury, MN. 1. To investigate the capability of DI for prediction of proximal femur and lumbar spine BMD; 2. To develop national diagnostic thresholds for DI in prediction of osteoporosis status with a reference population (American-Caucasian) of 500 (if prevalence of osteoporosis is 20%) post-menopausal females (50-90 years); 3. To investigate ability of Density Index + FRAX with BMI in fracture risk prediction; 4. To investigate correlation between lumbar spine or proximal femur BMD and Density Index in 140 men at wide age range (20-90 years), 70 with osteop

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2013-08
Est. Completion 2014-12
Bone Index Finland

3 total trials

Why NCT01935232 stopped before completion

NCT01935232 is an observational study that tracks outcomes without assigning an intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01935232 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01935232 about?

NCT01935232 is a clinical study titled "Bindex Ultrasonometer for Osteoporosis Diagnostics". Osteoporosis is a disease that leads to impaired skeletal strength and increased fracture risk. Among 200 million osteoporotic patients (Tarantino, Cannata et al. 2007) most are diagnosed only after a fracture. We expect with our aging population to see a significant increase in the prevalence of os...

What is the current status of trial NCT01935232?

This trial is currently terminated. The enrollment target is 135 participants. The study started on 2013-08. Estimated completion is 2014-12.

Who is sponsoring clinical trial NCT01935232?

This trial is sponsored by Bone Index Finland, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00870129 · 135 participants · NA

    Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

  • NCT03666000 · 135 participants · Phase 1

    Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • NCT04891510 · 135 participants · NA

    A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery

  • NCT05121051 · 135 participants · Phase 2

    Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01935232, the US trial registry maintained by the National Library of Medicine. NCT01935232 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.